Cancer Nursing Today Editors
The editors of Cancer Nursing Today are part of an experienced team of medical writers and researchers who report news and provide commentary related to oncology nursing.
Articles by Cancer Nursing Today Editors
A new study highlights the importance of effective management and close monitoring of GVHD.
A study of more than 10,000 patients illuminated the characteristics and needs of patients who are in remission.
Learn how an innovative rehabilitation model improved clinical outcomes and patient satisfaction with nursing care.
Learn about the diverse unmet needs and potential solutions related to the experiences of patients and caregivers.
New research shows that major depressive disorder is associated with certain outcomes in this population of patients.
The theme of this year’s meeting, “Ignite the Extraordinary,” inspired many attendees.
The meeting featured poster presentations, plenary sessions, and more.
The patients receiving a dose adjustment had a mean age of 72.2 years and 42.9% were women.
Patients with relapsed or refractory multiple myeloma are at an increased risk for severe infections.
Researchers conducted a pooled analysis of the MagnetisMM studies.
Nurses involved with the MajesTEC-1 study recommended several practices for infection monitoring and management.
The program hosted meetings for Black patients with mBC and patient advocates to develop educational materials.
The phase III TROPiCS-02 study compared sacituzumab govitecan, an antibody-drug conjugate, with single-agent chemotherapy.
To examine PROs and QOL, the researchers asked patients to complete 3 PRO tools.
At treatment discontinuation, 91% of patients in the FTD/TPI cohort remained at an ECOG performance status of 0 or 1.
APPs play a vital role in early recognition of symptoms of rheumatologic autoimmune diseases in patients with CLL.
Authors of the FRESCO-2 clinical trial reported on treatment-emergent AEs of special interest.
In addition, deepened or sustained responses were also seen in patients who went from weekly to biweekly elranatamab.
The Right Track educational program, created by The Multiple Myeloma Research Foundation, includes 3 critical components.
Dexamethasone can be safely stopped at 6 months in patients with multiple myeloma who have started combination therapies.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.